Antidepressant Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 20.70 Billion |
| Market Size (2029) | USD 28.90 Billion |
| CAGR (2024 - 2029) | 6.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Antidepressant Market Analysis
The Antidepressant Market size is estimated at USD 20.70 billion in 2024, and is expected to reach USD 28.90 billion by 2029, growing at a CAGR of 6.90% during the forecast period (2024-2029).
The pandemic has long and short-term impacts on the individual's mental illness, given the hurdles faced during the crisis, such as social isolation due to lockdown, job insecurity, and fear of being infected by the coronavirus. Hence, many researchers researched to find an effective treatment for the disease. For instance, as per the January 2022 research article, several shreds of evidence showed the potential therapeutic role of fluvoxamine for COVID-19. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) approved for treating obsessive-compulsive disorder. Moreover, a 2021 research study result demonstrated when participants were randomly assigned to fluvoxamine (Luvox, Abbott) at a dose of 100 mg twice for ten days or a corresponding placebo starting directly after randomization (day 1), treatment with fluvoxamine decreased the hospitalization need in high-risk outpatients with early diagnosed COVID-19. Thus, such trials during the pandemic surged the market growth and are expected to continue the upward trend over the forecast period due to increased awareness about mental health during the pandemic period.
The increasing number of cases of depression around the world, increasing awareness about depression, and the emergence of novel biologics are the significant factors driving the market growth. Depression mainly occurs due to the factors such as social isolation and stressful work environment, which contribute to increasing the number of people suffering from depression. It leads to increasing cases of suicide. The World Health Organization (WHO) data updated in September 2021 stated that depression is a prevalent mental illness, and according to estimates, around 5.0% of adults worldwide experience depression. Moreover, as per the same source, currently, the most significant cause of disability in the world is depression, which significantly contributes to the overall burden of the disease globally. Thus, such a high disease risk is creating demand for antidepressant use among the target population, thereby contributing to market growth.
Furthermore, in countries such as the UK and the US, characterized by their fast-paced economies, the percentage of the population affected by depression is high in every age group. For instance, according to the January 2022 data published by the Anxiety and Depression Foundation, generalized anxiety disorder affects 6.8 million adults annually or 3.1% of the US population. Thus, such a high prevalence is expected to drive the overall market growth over the forecast period.
However, the preference for non-pharmacological therapies over pharmacological ones and antidepressant drugs' side effects and patent expiry is likely to hinder the market growth over the forecast period.
Antidepressant Market Trends
Major Depressive Disorder Segment is Expected to Witness Considerable Growth Over the Forecast Period
Major depressive disorder or depression's possible causes comprise a combination of biological, psychological, and social sources of distress. The major risk factors include family history, significant life changes, certain medications, chronic health problems, and substance abuse. For treatment purposes, doctors generally prescribe antidepressants such as selective serotonin reuptake inhibitors (SSRIs).
The increasing number of cases of major depressive disorders across the globe is one of the significant factors propelling segment growth. For instance, as per the data published by WHO in September 2021, 5.7% of adults older than 60 years are suffering from depression, and approximately 280.0 million people globally have depression. Similarly, as per the January 2022 National Institute of Mental Health, an estimated 21.0 million adults in the US suffered from at least one major depressive episode. The number represented 8.4% of all US adults in 2020. Moreover, as per the January 2022 NCBI research article and as per Mordor Intelligence analysis, the prevalence of major depressive disorder (MDD) among the elderly is on the rise globally, and age and gender are few of the clinical and demographic variables that affect how often severe depression is among the elderly. Thus, the high burden of major depressive disorder globally is expected to surge the demand for antidepressants over the forecast period.
Moreover, the increasing recent developments related to the segment are also anticipated to drive the demand for antidepressants. For instance, in December 2021, Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders, received approval from the FDA for CAPLYTA (lumateperone) for the treatment of bipolar depression in adults. CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and adjunctive therapy with lithium or valproate. Such approvals for new products are anticipated to create new opportunities, thereby driving segment growth over the forecast period.
Therefore, the segment is expected to witness growth over the forecast period due to the abovementioned factors.
North America is Anticipated to Witness Significant Growth Over the Forecast Period
The increasing number of cases of depression is one of the major factors driving the overall growth of the antidepressant market in North America, particularly in the US, over the forecast period. Furthermore, the rise in the geriatric population and regional product launches are also expected to create more market opportunities. For instance, according to the 2021 Anxiety and Depression Association of America report, anxiety disorder is one of the most common mental illnesses in the US, affecting approximately 40 million American adults every year, which is 18.1% of the total population of the US. The same source also stated that more than 16.1 million American adults suffer from major depressive disorder yearly, which is more prevalent in women than men. Moreover, in May 2022, Pharmascience Canada, a division of Pharmascience Inc., launched its new generic drug, pms-LURASIDONE, in the Canadian market. Pms-LURASIDONE is a monotherapy for the management of the manifestations of schizophrenia in adults and adolescents (15-17 years of age). It is also helpful for acutely managing depressive episodes associated with bipolar disorder in adults and adolescents (13-17 years of age). Thus, the increasing prevalence of mental disorders and new product launches are expected to surge the demand for antidepressants, which in turn are further expected to drive the market in North America.
Key product launches, high concentration of market players or manufacturer's presence, acquisitions and partnerships among significant players, and increasing cases of mental disorders in the US are some factors driving the growth of the antidepressant market in the country. For instance, the data updated by the National Institute of Mental Health (NIMH) in January 2022 shows depression is one of the most common mental health disorders in the US, and an estimated 46.9% of adolescents with a major depressive episode and significant impairment received treatment in the previous year. Furthermore, the growing approvals and increasing pipeline products by crucial players concentrated in the country are also driving the studied market. For instance, in February 2022, AbbVie submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. Such developments are expected to drive market growth in the country.
Thus, given the factors above, the antidepressant market is expected to witness significant growth over the forecast period in North America.
Antidepressant Industry Overview
The market studied comprises a combination of multinational and domestic players. The entry barriers are comparatively less, and most drugs are available over the counter. The companies are actively involved in the global expansion of their product portfolio through partnerships, collaborations, and acquisitions. Some of the key players in the market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc., among others.
Antidepressant Market Leaders
-
GlaxoSmithKline PLC
-
Sanofi
-
AstraZeneca
-
Eli Lilly and Company
-
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Antidepressant Market News
- August 2022- the U.S. FDA approved dextromethorphan-bupropion, or Auvelity of Axsome Therapeutics, a drug used to treat major depressive disorder in adults. It is the first that works within a week of taking it.
- April 2022- pharmaceutical firm Lundbeck's antidepressant vortioxetine, sold under brand names Trintellix and Brintellix, demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the United States as Pristiq. The study investigated the efficacy of vortioxetine in patients with Major Depressive Disorder (MDD) who had a partial response to selective serotonin reuptake inhibitor (SSRI) treatment compared to desvenlafaxine.
Antidepressant Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cases of Depression Around the World
4.2.2 Increasing Awareness About Depression
4.2.3 Emergence of Novel Biologics
4.3 Market Restraints
4.3.1 Preference of Non-pharmacological Therapies over Pharmacological Therapies
4.3.2 Side Effects and Patent Expiry of Antidepressant Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 Product
5.1.1 Selective Serotonin Reuptake Inhibitor (SSRI)
5.1.2 Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
5.1.3 Tricyclic Antidepressant (TCA)
5.1.4 Monoamine Oxidase Inhibitor (MAOI)
5.1.5 Other Products
5.2 Depressive Disorder
5.2.1 Major Depressive Disorder
5.2.2 Obsessive-compulsive Disorder (OCD)
5.2.3 Generalized Anxiety Disorder (GAD)
5.2.4 Panic Disorder (PD)
5.2.5 Other Depressive Disorders
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbiVe Inc.
6.1.2 AstraZeneca
6.1.3 Eli Lilly and Company
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 H. Lundbeck AS
6.1.7 Merck & Co. Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Sun Pharmaceuticals Pvt. Ltd
6.1.11 Dr. Reddy's Laboratories
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Antidepressant Industry Segmentation
As per the scope of the report, antidepressant drugs are the drugs to treat major depressive disorders and other conditions, including dysthymia, anxiety disorders, obsessive-compulsive disorder (OCD), eating disorders, chronic pain, neuropathic pain, etc. The Antidepressant Market is segmented by product (Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-norepinephrine Reuptake Inhibitor (SNRI), Tricyclic Antidepressant (TCA), Monoamine Oxidase Inhibitor (MAOI), and other products), depressive disorder (Major Depressive Disorder, Obsessive-compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and other depressive disorders), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value in ( USD million) for the above segments.
| Product | |
| Selective Serotonin Reuptake Inhibitor (SSRI) | |
| Serotonin-norepinephrine Reuptake Inhibitor (SNRI) | |
| Tricyclic Antidepressant (TCA) | |
| Monoamine Oxidase Inhibitor (MAOI) | |
| Other Products |
| Depressive Disorder | |
| Major Depressive Disorder | |
| Obsessive-compulsive Disorder (OCD) | |
| Generalized Anxiety Disorder (GAD) | |
| Panic Disorder (PD) | |
| Other Depressive Disorders |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Antidepressant Market Research FAQs
How big is the Antidepressant Market?
The Antidepressant Market size is expected to reach USD 20.70 billion in 2024 and grow at a CAGR of 6.90% to reach USD 28.90 billion by 2029.
What is the current Antidepressant Market size?
In 2024, the Antidepressant Market size is expected to reach USD 20.70 billion.
Who are the key players in Antidepressant Market?
GlaxoSmithKline PLC, Sanofi, AstraZeneca, Eli Lilly and Company and Pfizer Inc. are the major companies operating in the Antidepressant Market.
Which is the fastest growing region in Antidepressant Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Antidepressant Market?
In 2024, the North America accounts for the largest market share in Antidepressant Market.
What years does this Antidepressant Market cover, and what was the market size in 2023?
In 2023, the Antidepressant Market size was estimated at USD 19.27 billion. The report covers the Antidepressant Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Antidepressant Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the key regulatory considerations for launching new Antidepressants?
The key regulatory considerations for launching new Antidepressants are a) Clinical trial requirements b) Safety and efficacy standards
What are the key regulatory considerations for launching new Antidepressants?
The key regulatory considerations for launching new Antidepressants are a) Clinical trial requirements b) Safety and efficacy standards
Antidepressant Industry Report
The antidepressants industry is on a significant upswing, fueled by the increasing prevalence of mental disorders and heightened awareness among the global population. This surge in demand for depression-managing medications is supported by robust research and development efforts aimed at introducing innovative treatments. With a diverse range of drug classes targeting disorders such as major depressive disorder and anxiety, the market is expanding across various distribution channels including hospital, retail, and online pharmacies. This growth is particularly notable in regions with high awareness and diagnosis rates, alongside emerging areas benefiting from improved healthcare. The industry's expansion is further underscored by statistics from Mordor Intelligence™, highlighting market share, size, and revenue growth, with forecasts and historical analyses available in a free report PDF download. This comprehensive outlook indicates the antidepressants market is poised for continued growth, driven by the essential need for effective mental health treatments and efforts to destigmatize mental health issues.
